Itoco Inc. (ITMC)
USD 0.01
(177.78%)
USD 0.01
(177.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -919.14 Thousand USD | 47.47% |
| 2022 | -1.74 Million USD | -68.08% |
| 2021 | -1.04 Million USD | 18.83% |
| 2020 | -1.28 Million USD | 47.41% |
| 2019 | -2.43 Million USD | -6.81% |
| 2018 | -2.28 Million USD | -41.28% |
| 2017 | -1.61 Million USD | -218.31% |
| 2016 | -507.78 Thousand USD | -25.44% |
| 2015 | -404.8 Thousand USD | 0.0% |
| 2013 | -2.26 USD | 0.0% |
| 2009 | -1.78 Million USD | -2682.86% |
| 2008 | -64.14 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -919.14 Thousand USD | 47.47% |
| 2023 Q3 | -239 Thousand USD | -2.64% |
| 2023 Q2 | -232.85 Thousand USD | 13.63% |
| 2023 Q4 | -177.69 Thousand USD | 25.65% |
| 2023 Q1 | -269.6 Thousand USD | 35.62% |
| 2022 FY | -1.74 Million USD | -68.08% |
| 2022 Q1 | -159.98 Thousand USD | -135.53% |
| 2022 Q4 | -418.77 Thousand USD | 47.43% |
| 2022 Q3 | -796.54 Thousand USD | -112.44% |
| 2022 Q2 | -374.95 Thousand USD | -134.37% |
| 2021 Q4 | 450.22 Thousand USD | 255.08% |
| 2021 FY | -1.04 Million USD | 18.83% |
| 2021 Q1 | -300.83 Thousand USD | 0.0% |
| 2021 Q2 | -251.67 Thousand USD | 16.34% |
| 2021 Q3 | -290.32 Thousand USD | -15.36% |
| 2020 FY | -1.28 Million USD | 47.41% |
| 2019 FY | -2.43 Million USD | -6.81% |
| 2018 FY | -2.28 Million USD | -41.28% |
| 2017 FY | -1.61 Million USD | -218.31% |
| 2016 FY | -507.78 Thousand USD | -25.44% |
| 2015 FY | -404.8 Thousand USD | 0.0% |
| 2013 FY | -2.26 USD | 0.0% |
| 2010 Q3 | -182.45 Thousand USD | 3.49% |
| 2010 Q2 | -189.04 Thousand USD | 3.7% |
| 2010 Q1 | -196.31 Thousand USD | 88.77% |
| 2009 Q1 | -15.66 Thousand USD | -54.37% |
| 2009 Q3 | -6723.00 USD | 57.39% |
| 2009 Q4 | -1.74 Million USD | -25900.57% |
| 2009 Q2 | -15.77 Thousand USD | -0.75% |
| 2009 FY | -1.78 Million USD | -2682.86% |
| 2008 Q4 | -10.14 Thousand USD | 1.2% |
| 2008 Q1 | -34.37 Thousand USD | 0.0% |
| 2008 Q3 | -10.26 Thousand USD | -9.77% |
| 2008 Q2 | -9354.00 USD | 72.79% |
| 2008 FY | -64.14 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 31.173% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 81.779% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 94.85% |
| Nascent Biotech, Inc. | -2.22 Million USD | 58.781% |
| Rebus Holdings, Inc. | -664 Thousand USD | -38.425% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.123% |
| Qrons Inc. | -643.67 Thousand USD | -42.795% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -135.937% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.344% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -121.224% |
| Skye Bioscience, Inc. | -13.67 Million USD | 93.277% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.72% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 118.701% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -251.184% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.788% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 67.755% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 40.162% |
| Mesoblast Limited | -84.14 Million USD | 98.908% |
| Marizyme, Inc. | -34.08 Million USD | 97.304% |
| Genus plc | 6.4 Million USD | 114.362% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 109.434% |
| Pharming Group N.V. | -4.87 Million USD | 81.163% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 53.73% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 1.314% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 88.992% |
| ContraFect Corporation | -56.88 Million USD | 98.384% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 79.82% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 34.44% |
| IMV Inc. | -38.67 Million USD | 97.623% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 66.587% |
| MultiCell Technologies, Inc. | -722.81 USD | -127062.048% |
| ONE Bio Corp. | 13.68 Million USD | 106.718% |
| Accustem Sciences Inc. | -3.74 Million USD | 75.466% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.442% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -90.274% |
| Q BioMed Inc. | -3.44 Million USD | 73.324% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 125.964% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 65.019% |
| Biomind Labs Inc. | -1 Million USD | 8.96% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.328% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 68.319% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 86.174% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 50.7% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2968.71% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 94.208% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 52.44% |
| GB Sciences, Inc. | -1.42 Million USD | 35.295% |
| Alpha Cognition Inc. | -9.7 Million USD | 90.53% |
| HST Global, Inc. | -140.9 Thousand USD | -552.303% |
| CSL Limited | 3.7 Billion USD | 100.025% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 18.292% |
| Halberd Corporation | -75.05 Thousand USD | -1124.704% |
| Enzolytics Inc. | -2.14 Million USD | 57.225% |
| Agentix Corp. | -1.37 Million USD | 32.995% |
| Resverlogix Corp. | -12.74 Million USD | 92.79% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 70.989% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.784% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 11.96% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 68.517% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 41.803% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 73.006% |
| AVAX Technologies, Inc. | 6.69 Million USD | 113.733% |
| Zenith Capital Corp. | -8.94 Million USD | 89.722% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.779% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5176.046% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 62.565% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -435.912% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 54.152% |
| Kadimastem Ltd | -3.04 Million USD | 69.768% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 6.596% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 26.82% |
| BioStem Technologies, Inc. | -7.77 Million USD | 88.184% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -406.455% |
| LadRx Corporation | -3.82 Million USD | 75.962% |
| Cell Source, Inc. | -4.32 Million USD | 78.75% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -33.8% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -33.8% |
| NovAccess Global Inc. | -2.46 Million USD | 62.739% |
| Affymax, Inc. | -15.04 Million USD | 93.891% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 78.314% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 17.861% |
| Mobile Lads Corp. | -554.55 Thousand USD | -65.745% |
| CytoDyn Inc. | -18.05 Million USD | 94.91% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -3551.728% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -317.643% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -62.759% |
| SYBLEU INC | -149.18 Thousand USD | -516.128% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 49.395% |
| International Stem Cell Corporation | -663 Thousand USD | -38.633% |
| Bioxytran, Inc. | -3.82 Million USD | 75.94% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1646.087% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -4418.879% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 97.466% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 43.193% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -24.911% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 70.455% |
| Neutra Corp. | -229.48 Thousand USD | -300.521% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 94.759% |
| PureTech Health plc | -146.19 Million USD | 99.371% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 95.723% |
| IXICO plc | -1.43 Million USD | 36.038% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 90.316% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.245% |
| CSL Limited | 3.81 Billion USD | 100.024% |
| Cellectis S.A. | -108.85 Million USD | 99.156% |